Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Claire Dingremont
Observed names:
C Dingremont,
C. Dingremont,
C.L. Dingremont
Institution:
Centre Hospitalier de Bigorre
Observed institutions:
Centre Hospitalier Universitaire Henri-Mondor,
Centre Hospitalier de Bigorre,
Hôpital Rangueil,
Hôpital Larrey,
Hôpitaux Universitaires Henri-Mondor
OpenAlex ID:
A5036932794
Clinical features and prognostic factors of listeriosis: the MONALISA national prospective cohort study
2017
·
Caroline Charlier
, Élodie Perrodeau
, et al.
·
The Lancet Infectious Diseases
·
665
PDF
Risk factors for bleeding, including platelet count threshold, in newly diagnosed immune thrombocytopenia adults
2018
·
M.‐L. Piel‐Julian
, M. Mahévas
, et al.
·
Journal of Thrombosis and Haemostasis
·
162
PDF
Isatuximab, lenalidomide, dexamethasone and bortezomib in transplant-ineligible multiple myeloma: the randomized phase 3 BENEFIT trial
2024
·
Xavier Leleu
, Cyrille Hulin
, et al.
·
Nature Medicine
·
152
PDF
Newly diagnosed immune thrombocytopenia adults: Clinical epidemiology, exposure to treatments, and evolution. Results of the CARMEN multicenter prospective cohort
2017
·
Guillaume Moulis
, Johanne Germain
, et al.
·
American Journal of Hematology
·
102
PDF
Angioedema Due to Acquired C1-Inhibitor Deficiency Without Hematological Condition: A Multicenter French Cohort Study of 34 Patients
2025
·
Romain Stammler
, Federica Defendi
, et al.
·
The Journal of Allergy and Clinical Immunology In Practice
·
8
PDF
The CARMEN-France registry of adult patients with immune thrombocytopenia and autoimmune hemolytic anemia in France
2024
·
Guillaume Moulis
, Marc Michel
, et al.
·
La Revue de Médecine Interne
·
8
High-Risk Multiple Myeloma in Benefit (IFM 2020-05) Phase 3 Randomized Study of Isatuximab (Isa) Plus Lenalidomide and Dexamethasone (Rd) with Bortezomib Versus Isard in Patients with Newly Diagnosed Transplant Ineligible Multiple Myeloma (NDMM TI)
2024
·
Jill Corre
, Jérôme Lambert
, et al.
·
Blood
·
4
Dermatopolymyosite et cancer: étude rétrospective de 12 cas parmi une cohorte de 50. Évolution et facteurs prédictifs
1998
·
R Cozac Batut
, H Juchet
, et al.
·
La Revue de Médecine Interne
·
4
Pretreatment with standard‐dose intravenous methylprednisolone does not improve outcomes in newly diagnosed immune thrombocytopenia ( ITP )
2018
·
Anaïs Essilini
, Thibault Comont
, et al.
·
European Journal Of Haematology
·
3
Clinical Epidemiology and First-Line Treatment in Immune Thrombocytopenia Adults. Results of the Carmen Prospective Cohort
2015
·
Guillaume Moulis
, Thibault Comont
, et al.
·
Blood
·
3
Sustained minimal residual disease (sMRD) negativity in transplant ineligible newly diagnosed multiple myeloma treated with isatuximab plus lenalidomide and dexamethasone with bortezomib (Isa-VRd) versus isa-rd: 12-24-month data from the phase 3 benefit trial (IFM 2020-05)
2025
·
Arthur Bobin
, Jerome Lambert
, et al.
·
Blood
·
2
Multicenter Open Label Phase 3 Benefit Study of Isatuximab Plus Lenalidomide and Dexamethasone with/without Bortezomib in the Treatment of Newly Diagnosed Non-Frail Transplant Ineligible Multiple Myeloma Elderly Patients. IFM2020-05
2023
·
Arthur Bobin
, Cyrille Hulin
, et al.
·
Blood
·
2
Multicenter Open Label Phase 3 Study of Isatuximab Plus Lenalidomide and Dexamethasone with/without Bortezomib in the Treatment of Newly Diagnosed Non-Frail Transplant Ineligible Multiple Myeloma Elderly Patients (≥ 65; < 80 Years). IFM2020-05/Benefit
2022
·
Arthur Bobin
, Jerome Lambert
, et al.
·
Blood
·
2
Le syndrome de la rate baladeuse : cas clinique
2020
·
J.-T. Giraud
, C. Dingremont
, et al.
·
La Revue de Médecine Interne
·
2
Effet antalgique d’une perfusion de bisphosphonates à la phase aiguëd’un tassement vertébral ostéoporotiquechez le sujet âgé
2000
·
B Godfrin
, M Alvarez
, et al.
·
La Revue de Médecine Interne
·
2
Des ongles jaunes
1998
·
M Auvinet
, S Dahan
, et al.
·
La Revue de Médecine Interne
·
2
Apixaban pharmacokinetics in newly diagnosed multiple myeloma patients treated in the benefit and isasocut clinical trials: The apixabor/mibapix study
2025
·
Emilie Chalayer
, Elisabeth Daguenet
, et al.
·
Blood
·
1
PDF
Hairy kydneys unusual
2021
·
Christophe Ferreira de Matos
, Claire Dingremont
, et al.
·
Hématologie
·
1
Intérêt d’initier la corticothérapie à dose conventionnelle par méthylprednisolone intraveineuse dans le purpura thrombopénique immunologique nouvellement diagnostiqué de l’adulte
2016
·
A. Essilini
, T. Comont
, et al.
·
La Revue de Médecine Interne
·
1
Incidence of Adverse Drug Reactions Related to Immune Thrombocytopenia Drugs. A Prospective Cohort Study
2015
·
Salim Mezaache
, Thibault Comont
, et al.
·
Blood
·
1
A propos des lipomatoses cortico-induites: la lipomatose prémalaire
1997
·
P Ariel
, H Juchet
, et al.
·
La Revue de Médecine Interne
·
1
≪ Syndrome de la tortue ≫: chute et rhabdomyolyse chez le sujet âgé
1997
·
S Ollier
, C Dingremont
, et al.
·
La Revue de Médecine Interne
·
1
Longitudinal assessments of MRD in high‐risk newly diagnosed transplant‐ineligible multiple myeloma in the BENEFIT study (IFM2020‐05)
2026
·
Jill Corre
, Jerome Lambert
, et al.
·
HemaSphere
PDF
OA-52 Isatuximab Plus Lenalidomide and Dexamethasone With Bortezomib Versus Isatuximab Plus Lenalidomide and Dexamethasone in Newly Diagnosed Transplant Ineligible Multiple Myeloma: The Benefit Study
2024
·
Xavier Leleu
, Cyrille Hulin
, et al.
·
Clinical Lymphoma Myeloma & Leukemia
Exposition, efficacité et sécurité en vie réelle du romiplostim en France. Données du registre CARMEN-France
2024
·
G. Moulis
, M. Mahevas
, et al.
·
La Revue de Médecine Interne
Show more works
View as search
Works count:
52
Citation count:
1,129
H-index:
6
I10-index:
4
Year
Topic
Type